Dynamics of lamivudine-resistant hepatitis B virus during adefovir monotherapy versus lamivudine plus adefovir combination therapy

Journal of Medical Virology

Volumn 80, Issue 7, 2008, Pages 1160-1170

  Ijaz, Samreen ^a   Arnold, Catherine ^a   Dervisevic, Samir ^b   Mechurova, Jana ^c   Tatman, Nick ^c   Tedder, Richard S ^a,b   Naoumov, Nikolai V ^c  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Adefovir resistance; HBV populations; Pyrosequencing; Rescue therapy

Indexed keywords

ADEFOVIR; LAMIVUDINE;

ADULT; ANTIBIOTIC RESISTANCE; ARTICLE; CLINICAL ARTICLE; DYNAMICS; FEMALE; HEPATITIS B VIRUS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LIVER FUNCTION TEST; MALE; MONOTHERAPY; PYROSEQUENCING; TREATMENT OUTCOME; VIREMIA;

ADENINE; ADULT; ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; PHOSPHONIC ACIDS; POLYMORPHISM, SINGLE NUCLEOTIDE; REVERSE TRANSCRIPTASE INHIBITORS;

HEPATITIS B VIRUS;

EID: 43949100672     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.21206     Document Type: Article

References (27)

1. Benhamou Y, Bochet M, Thibault V, Calvez V, Fievet MH, Vig P, Gibbs CS, Brosgart C, Fry J, Namini H, Kaltama C, Poynard T. 2001. Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: An open-label pilot study. Lancet 358:718-723.
2. Da Silva LC, Pinho JR, Sitnik R, Da Fonseca LE, Carrilho FJ. 2001. Efficacy and tolerability of long-term therapy using high lamivudine doses for the treatment of chronic hepatitis B. J Gastroenterol 36:476-485.
3. Dienstag JL, Schiff ER, Wright TL, Perrillo RP, Hann HW, Goodman Z, Crowther L, Condreay LD, Woessner M, Rubin M, Brown NA. 1999. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 341:1256-1263.
4. Fung SK, Chae HB, Fontana RJ, Conjeevaram H, Marrero J, Oberhelman K, Hussain M, Lok AS. 2006. Virologic response and resistance to adefovir in patients with chronic hepatitis B. J Hepatol 44:283-290.
5. Garson JA, Grant PR, Ayliffe U, Ferns RB, Tedder RS. 2005. Real-time PCR quantitation of hepatitis B virus DNA using automated sample preparation and murine cytomegalovirus internal control. J Virol Methods 126:207-213.
6. Hussain M, Fung S, Libbrecht E, Sablon E, Cursaro C, Andreone P, Lok AS. 2006. Sensitive line probe assay that simultaneously detects mutations conveying resistance to lamivudine and adefovir. J Clin Microbiol 44:1094-1097.
7. Lai CL, Chien RN, Leung NW, Chang TT, Guan R, Tai DI, Ng KY, Wu PC, Dent JC, Barber J, Stephenson SL, Gray DF. 1998. A one year trial of lamivudine for chronic hepatitis B. N Engl J Med 339:61-68.
8. Lampertico P, Vigano M, Manenti E, Iavarone M, Lunghi G, Colombo M. 2005. Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine. Hepatology 42:1414-1419.
9. Lampertico P, Vigano M, Manenti E, Iavarone M, Sablon E, Colombo M. 2007. Low resistance to adefovir combined with lamivudine: A 3-year study of 145 lamivudine-resistant hepatitis B patients. Gastroenterology 133:1445-1451.
10. Lee YS, Suh DJ, Lim YS, Jung SW, Kim KM, Lee HC, Chung YH, Lee YS, Yoo W, Kim SO. 2006. Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy. Hepatology 43:1385-1391.
11. Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, Tanwandee T, Tao QM, Shue K, Keene ON, Dixon JS, Gray DF, Sabbat J. 2004. Cirrhosis Asian Lamivudine Multicentre Study Group. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 351:1521-1531.
12. Liaw YF, Leung N, Guan R, Lau GK, Merican I, McCaughan G, Gane E, Kao JH, Omata M. 2005. Asian-Pacific consensus statement on the management of chronic hepatitis B: A 2005 update. Liver Int 25:472-489.
13. Liaw YF, Lee CM, Chien RN, Yeh CT. 2006. Switching to adefovir monotherapy after emergence of lamivudine-resistant mutations in patients with liver cirrhosis. J Viral Hepatitis 13:250-255.
14. Lindstrom A, Odeberg J, Albert J. 2004. Pyrosequencing for the detection of lamivudine-resistant hepatitis B virus. J Clin Microbiol 42:4788-4795.
15. Melegari M, Scaglioni PP, Wands JR. 1998. Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective. Hepatology 27:628-633.
16. Mihm U, Gartner BC, Faust D, Hofmann WP, Sarrazin C, Zeuzem S, Hermann E. 2005. Viral kinetics in patients with lamivudine-resistant hepatitis B during adefovir-lamivudine combination therapy. J Hepatol 43:217-224.
17. Ono SK, Kato N, Shiratori Y, Kato J, Goto T, Schinazi RF, Carrilho FJ, Omata MI. 2001. The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance. J Clin Invest 107:449-455.
18. Osiowy C, Villeneuve JP, Heathcote EJ, Giles E, Borlang J. 2006. Detection of rtN236T and rtA181V/T mutations associated with resistance to adefovir dipivoxil in samples from patients with chronic hepatitis B virus infection by the INNO-LiPA HBV DR line probe assay (version 2). J Clin Microbiol 44:1994-1997.
19. Pallier C, Castera L, Soulier A, Hezode C, Nordmann P, Dhumeaux D, Pawlotsky JM. 2006. Dynamics of hepatitis B virus resistance to lamivudine. J Virol 80:643-653.
20. Papatheodoridis GV, Dimou E, Dimakopoulos K, Manolakopoulos S, Rapti I, Kitis G, Tzourmakliotis D, Manesis E, Hadziyannis SJ. 2005. Outcome of hepatitis B e antigen-negative chronic hepatitis B on long-term nucleos(t)ide analog therapy starting with lamivudine. Hepatology 42:121-129.
21. Perrillo R, Schiff E, Yoshida E, Statler A, Hirsch K, Wright T, Gutfreund K, Lamy P, Murray A. 2000. Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants. Hepatology 32:129-134.
22. Perrillo R, Hann HW, Mutimer D, Willems B, Leung N, Lee WM, Moorat A, Gardner S, Woessner M, Bourne E, Brosgart CL, Schiff E. 2004. Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus. Gastroenterology 126:81-90.
23. Peters MG, Hann HW, Martin P, Heathcote EJ, Buggisch P, Rubin R, Bourliere M, Kowdley K, Trepo C, Gray D, Sullivan M, Kleber K, Ebrahimi R, Xiong S, Brosgart CL. 2004. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology 126:91-101.
24. Pugh JC, Weber C, Houston H, Murray K. 1986. Expression of the X gene of hepatitis B virus. J Med Virol 20:229-246.
25. Schiff ER, Lai CL, Hadziyannis S, Neuhaus P, Terrault N, Colombo M, Tillmann HL, Samuel D, Zeuzem S, Lilly L, Rendina M, Villeneuve JP, Lama N, James C, Wulfsohn MS, Namini H, Westland C, Xiong S, Cioy GS, Van Doren S, Fry J, Brosgart CL. 2003. Adefovir Dipovoxil Study 435 International Investigators Group. Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre-and post-liver transplantation patients. Hepatology 38:1419-1427.
26. Villet S, Pichoud C, Villeneuve JP, Trepo C, Zoulim F. 2006. Selection of a multiple drug-resistant hepatitis B virus strain in a liver-transplanted patient. Gastroenterology 131:1253-1261.
27. Yim HJ, Hussain M, Liu Y, Wong SN, Fung SK, Lok AS. 2006. Evolution of multi-drug resistant hepatitis B virus during sequential therapy. Hepatology 44:703-712.